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Abstract 
Purpose: To investigate the dual effect of angiotensin blockade by irbesartan and enalapril on 
proteinuria in diabetic patients with azotemia. 
Methods: Patients with diabetes of > 5 years duration, proteinuria at a nephrotic level and serum 
creatinine > 1.5 mg/dL were enrolled in the study. Forty-five enrolled patients were divided into three 
groups, those receiving enalapril , irbesartan, or enalapril plus irbesartan, respectively, over a period of 
24 weeks. Urinary protein excretion and serum level of albumin, creatinine, potassium were measured 
before and after treatment  
Results: In patients receiving enalapril, irbesartan, and both drugs concomitantly, mean urinary protein 
excretion level decreased significantly at the end of 6 months from 6.46 ± 4.66 to 3.36 ± 1.60, 5.89 ± 
5.34 to 3.22 ± 1.72 and 5.99 ± 3.77 to 2.10 ± 2.22 g/day, respectively (p = 0.001). Decrease in 
proteinuria in the group receiving the combined therapy was more significant than the other two groups 
(p = 0.025). During the period of therapy, serum albumin increased and mean arterial pressure 
decreased significantly (p = 0.02 and p = 0.002, respectively) but serum creatinine and potassium and 
creatinine clearance values showed insignificant increases (p = 0.28 and p = 0.57, respectively). 
Conclusion: The combined use of enalapril and irbesartan, in patients with diabetic nephropathy 
associated with azotemia, is more effective in decreasing proteinuria without causing any substantial 
increase in serum potassium levels. The combined use of these two drugs shows a more pronounced 
anti-proteinuric effect. 
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Hypertension is a risk factor that exacerbates all 
vascular complications of diabetes and strongly 
influences the prognosis of the disease. 
Therefore, controlling concomitant hypertension 
in diabetic patients is at least as important as the 
control of diabetes [1]. 
 
In patients with diabetic nephropathy, proteinuria 
cannot be avoided and, if it lasts for a long 
period, the rapid development of end-stage renal 
failure is inevitable due to damaging effects of 
proteinuria on glomerules and tubules. In 
addition, hypoalbuminemia, resulting from 
proteinuria, is an important cause of mortality 
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and morbidity in patients with diabetic 
nephropathy [2]. In recent years, it has been 
demonstrated in several studies that anti-
hypertensive drugs belonging to the classes of 
angiotensin-converting enzyme inhibitors (ACEI) 
and angiotensin II (ATII) receptor blockers, 
reduce proteinuria and exert renoprotective 
effects, in particular, by decreasing glomerular 
filtration rate (GFR) as well as by lowering blood 
pressure [2]. Recently, combination therapy of 
ACEIs and ATII receptor blockers has been 
considered in order to reduce proteinuria in 
patients with diabetic nephropathy. The main 
rationale for this combination is that the formation 
of ATII is not completely inhibited by ACEIs and 
that ATII receptor blockers can completely inhibit 
the effects of ATII resulting from by pathways [2]. 
Beneficial effects expected from both single and 
combined use of ACEIs and ATII receptor 
blockers in patients with diabetic nephropathy 
are reduced proteinuria as well as lowered blood 
pressure [3]. The effects of ACEIs as well as ATII 
receptor blockers on proteinuria and renal 
function in patients with mild to moderate renal 
failure and azotemia is a recent area under 
focus. 
 
The principal objective of the present study was 
to test whether a difference exists between 
ACEIs and ATII receptor blockers with respect to 
their ability to delay impairment of renal function 
by reducing proteinuria in patients with diabetic 
nephropathy with azotemia. This study also 




A total of 45 patients, including 22 women and 23 
men, were included in the clinical study. They 
were hospitalized in either the Clinics of Internal 
Medicine or presented to outpatient clinics of 
Internal Medicine of the Medical School of 
Ataturk University. The study was approved 
(2004-6/3) by the Medical School of Ataturk 
University Ethics Committee according to the 
Declaration of Helsinki and each subject gave 
informed consent to participate. 
 
Patient selection and study design 
 
Study participants had a diagnosis of diabetic 
nephropathy due to type 2 diabetes mellitus 
(DM), or were being followed for this diagnosis. 
Patients with creatinine levels above 1.5 mg/dL 
and with proteinuria of a nephrotic level 
(proteinuria ≥ 3.5 g/day) were enrolled in the 
study. Their average age was 52.5 ± 4.4 years 
(range: 43 - 74 years) and their duration of 
diabetes was 7.2 ± 2.6 (5 - 14) years. Selected 
demographic and clinical parameters of the 45 
patients who underwent baseline testing are 
shown in Table I.  
 
The patients included in the study were divided 
into three groups; the first group was given 
enalapril 10 mg/day, the second group irbesartan 
300 mg/day, and the third group enalapril 10 
mg/day plus irbesartan 300 mg/day. Known 
diabetes duration and oral antidiabetic 
medications in use by the patients were 
recorded. The effects of the drugs on proteinuria, 
electrolytes, renal function tests and mean 
arterial pressure were compared. Patients 
without secondary hypertension, with duration of 
diabetes greater than five years, a serum 
creatinine level above 1.5 mg/dL, proteinuria of 
nephrotic level, a body mass index below 30, and 
with diastolic blood pressure not exceeding 100 
mmHg were included in the study. 
 
Blood pressure measurement 
 
Arterial tension values of the patients were 
measured with an ERKA sleeve 
sphygmomanometer. Patients rested 15 minutes 
prior to measurement. Measurements were taken 
twice from the right arm of sitting patients at 
intervals of five minutes. The results of the two 
measurements were averaged. Mean arterial 
pressure (MAP) was calculated in the patients 
according to the following formula: diastolic 
pressure + 1/3 (systolic pressure - diastolic 
pressure). 
 
Biochemical specimen collection 
 
Morning venous blood samples were taken from 
the patients following 10 to 12 h of fasting and 
biochemical parameters were studied. Fasting 
blood glucose (FBG), sodium (Na), potassium 
(K+), uric acid (UA), blood urea nitrogen (BUN) 
and creatinine were routinely studied in the 
central biochemical laboratory of our hospital.  
 
During the study period, relevant biochemical 
parameters of the blood samples and the level of 
proteinuria were monitored once in two months 
starting from day 15. Following initiation of drug 
treatment, renal function, especially serum 
electrolytes, were monitored closely. For 
proteinuria determination in urine, the result 
based on protein (g/dL) and creatinine (g/dL) 
values in the first morning urine sample and 
urinary protein/creatinine ratio (U P/Cr) were 
considered as g/g proteinuria. For each patient, 
these values were determined twice every other 
day and the mean of these results were taken. 
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Creatinine clearance and proteinuria 
measurement 
 
Estimated creatinine clearance (eCrCl) was 
calculated using Cockcroft-Gault equation [(140-
age) x weight/72 x serum creatinine] x 0.85 for 
female. The patients received a diet containing 
0.8 g/kg of protein and 100 mmol of sodium. 
During the study period, therapies that might 
have changed the efficacy of the treatments 
(e.g., diuretic and albumin use) were avoided. 
 
During the study period, biochemical blood 
samples and the amount of proteinuria were 
studied once in two months starting from day 15. 
Following initiation of drug treatment, renal 
function, especially serum electrolytes, were 
monitored closely. For proteinuria determination 
in the urine, the result based on protein (g/dL) 
and creatinine (g/dL) values in the first morning 
urine sample and urinary protein/creatinine ratio 
(U P/Cr) were considered as g/g proteinuria. For 
each patient, these values were determined 
twice every other day and the average of these 
results were considered. 
 
Statistical analysis  
 
Arithmetic means and standard deviations of the 
values obtained at the end of the study were 
calculated. These values were presented as 
mean ± standard deviation. SPSS for Windows, 
version 11.5 (Chicago, Illinois, USA) was used 
for statistical analysis. In-group changes between 
pre- and post-treatment values were calculated 
separately by Wilcoxon-rank test in both groups. 
Post-treatment values were calculated separately 
by Wilcoxon-rank test in both groups. Linear 
regression analysis was used to determine 
factors affecting differences in proteinuria. age, 
sex, differences in MAP, systolic and diastolic 
blood pressure, creatinine clearance (CrCl), 
serum creatinine (sCr), potassium, sodium, 
albumin and medications were included as 
independent variables. Kruskal-Wallis variance 
analysis was used to determine differences in 
therapeutic outcomes among the three groups. 
Relationships between numeric variables were 
tested using the Spearman correlation analysis. 
A statistical significance level of p < 0.05 was 




MAP, SBP, DBP, sCr levels, eCrCl, serum 
albumin levels and urinary protein/creatinine 
ratio, as well as age and sex distribution were not 
significantly different among these three groups 
at baseline (p > 0.05) (Table 1). 
 
Proteinuria and serum albumin levels in the 
study groups 
 
As seen in Table II; at month six, proteinuria 
levels in the patients receiving enalapril, 
irbesartan and the combination treatment had 
decreased from 6.46 ± 4.66 to 3.36 ± 1.60 g/day; 
5.89 ± 5.34 to 3.22 ± 1.72 g/day, and 5.99 ± 3.77 
to 2.10 ± 2.22 g/day, respectively (p = 0.001). 
When the therapeutic efficacy at month 6 was 
evaluated based on proteinuria levels, it was 
found that there was no significant difference 
between enalapril and irbesartan groups (p = 
0.56). However, decrease of proteinuria in the 
group receiving combined treatment was found 
to be more significant than the other two groups 
(Kruskal-Wallis, p = 0.025, mean differences in 
enalapril, irbesartan and combination groups 3.1, 
2.67 and 3.89 respectively). Multinomial linear 
regression analysis showed no relationship 
between proteinuria and the level of decreases of 
MAP or the other investigated variables (ANOVA: 
F = 0.996, p = 0.470).  
 
Serum albumin levels in the patients receiving 
enalapril or irbesartan increased from 3.22 ± 0.17 
to 3.40 ± 0.54 g/dL and 3.17 ± 0.57 to 3.42 ± 




Table 1: Demographic profile and clinical characteristics of patients 
 
Parameter Enalapril Irbesartan Combination P-value 
Sex (female/male)  8/7 7/8 7/8 NS 
Age (years) 51.6 ± 4.5 53.2 ±3.4 52.7 ± 3.8 NS 
MAP (mmHg) 103.53 ± 9.04 106.46 ± 10.3 105.26 ± 4.89 NS 
SBP (mmHg) 145.33 ± 14.0 146.67 ± 14.4 147.1 ± 10.2 NS 
DBP (mmHg) 84.0 ± 9.1 85.6 ± 9.02 84.33 ± 5.6 NS 
sCr (µmol/L) 191.84±48.4 197.12±66.9 189.2±57.2 NS 
eCrCl (ml/min) 38.39±6.8 38.80±11.99 41.23±10.4 NS 
Serum albumin (g/dL) 3.22 ± 0.17 3.17 ± 0.57 3.23 ± 0.45 NS 
U P/Cr (g/g) 6.46 ± 4.66 5.89 ± 5.34 5.99 ± 3.77 NS 
eCrCl: estimated creatinine clearance, DBP: diastolic blood pressure, SBP: systolic blood pressure, sCr: serum 
creatinine, MAP: mean arterial blood pressure, NS: not significant, U P/Cr: urinary protein/creatinine ratio 
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These increases were statistically significant (p = 
0.03, p = 0.02, respectively) (Table 2). 
Furthermore, treatment with enalapril plus 
irbesartan significantly increased the serum 
levels of albumin (p = 0.02). However,  no 
significant difference was found in the correlation 
analysis performed to test for a relationship 
between the decrease in proteinuria level and the 
increase in serum albumin level in the patients 
receiving enalapril and irbesartan (r = -0.96, p = 
0.56, r = 0.227, p = 0.16, respectively). Similarly, 
the increase in serum albumin level in the group 
receiving combination therapy was found to be 
independent of proteinuria (r = 0.23, p = 0.15). 
 
Serum creatinine, CrCl, serum potassium and 
HbA1c levels  
 
Increases in serum creatinine and CrCl levels of 
the patients receiving enalapril, irbesartan or 
combination therapy of enalapril and irbesartan 
were not significant. Pre- and post-treatment 
serum potassium levels in all three groups 
receiving treatment remained within normal 
limits. No patient developed hyperkalaemia 
requiring interruption of the treatment. Similarly, 
no significant differences were found with respect 
to serum potassium levels (p = 0.64) at month six 
for any treatment. HbA1c levels had significantly 
decreased in all treatment groups (p = 0.001) by 
the end of month six (Table 2). 
 
Systolic-diastolic blood pressure and MAP levels  
Significant differences were found in each of 
three groups (enalapril, irbesartan and 
combination) with respect to baseline and post-
treatment systolic blood pressure values (p = 
0.001, p = 0.006, p = 0.002, respectively) (Table 
2). The same magnitude of systolic blood 
pressure decrease was observed in all three 
groups (no significant difference between groups, 
p = 0.421). 
 
Differences were found in each of three groups 
with respect to baseline and post-treatment 
diastolic blood pressure values (p = 0.07, 0.028, 
0.02 for enalapril group, inbesatan and 
combination therapy group, respectively; Table 
2). The same magnitude of diastolic blood 
pressure decrease was observed in all three 
groups (no significant difference between groups, 
p = 0.528). 
 
A significant decrease in MAP became apparent 
during month two, and this decrease continued 
until the end of the study. In the group receiving 
enalapril, there was a significant decrease (p = 
0.002) in the MAP values at month 6 when 
compared to pre-treatment values. Also MAP 
values significantly decreased in the groups 
receiving irbesartan (p = 0.002) and enalapril 
plus irbesartan (p = 0.002) at month six when 
compared to pre-treatment values (Table 2). 
 
 
Table 2: Prior and post-treatment results for the study groups  
 
Variable Enalapril  Irbesartan  Combination 
 Prior Post- P-value  Prior Post-  
P-
value 
 Prior Post-  P-value 
MAP 
(mmHg) 103.53±9.0 92.0±9.0 0.002  106.46±10.3 93.9±11.2 0.002  105.26±4.89 91.26±5.82 0.002 
SBP 
(mmHg) 145.33±14.0 131.33±7.1 0.001  146.67±14.4 133.31±9.5 0.006  147.1±10.2 130.08±6.32 0.002 
DBP 
(mmHg) 84.0 ± 9.1 81.0 ± 8.2 0.07  85.6 ± 9.02 83.6 ± 6.11 0.028  84.33 ± 5.6 80.09 ± 6.92 0.02 
U P/Cr (g/g) 6.46±4.66 3.36±1.60 0.001  5.89±5.34 3.22±1.72 0.001  5.99±3.77 2.10±2.22 0.001 
sAlb 
(g/dL) 3.22±0.17 3.40±0.54 0.03  3.17±0.57 3.42±0.56 0.02  3.23±0.45 3.51 ± 0.72 0.02 
sCr 
(µmol/L) 191.84±48.4 195.36±51.0 0.5  197.12±66.9 202.4±62.5 0.22  189.2±57.2 203.28±44.9 0.28 
eCrCl 
(ml/min) 38.39±6.8 37.7±6.7 0.06  38.80±11.99 37.5±10.6 0.11  41.23±10.4 40.76±10.0 0.57 
sK+ (mEq/L) 4.90±0.51 5.06±0.58 0.16  4.67±0.66 4.88±0.69 0.27  4.66±0.54 4.711±0.56 0.70 
HbA1c 
(%) 8.90±0.60 7.10±0.22 0.001  8.8±0.73 7.21±0.36 0.001  9.02±2.7 7.32±1.17 0.001 
eCrCl: estimated creatinine clearance; DBP: diastolic blood pressure; SBP: systolic blood pressure; MAP: mean 
arterial blood pressure; PU: proteinuria; sAlb: serum albumin; sCr: serum creatinine; sK+: serum potassium; U 
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Several studies have demonstrated that ATII 
receptor blockers and ACEIs have anti-
proteinuric and renoprotective effects in both 
diabetic and non-diabetic patients. It was seen 
that anti-proteinuric effects in both groups were 
not significantly different when anti-proteinuric 
effects in the patients receiving enalapril and 
irbesartan were compared. The decrease in 
proteinuria in the third group receiving 
combination therapy was found to be significant 
compared to other groups. 
 
A number of studies have found that in patients 
with diabetic nephropathy, ACEI and ATII 
receptor blockers delay end-stage renal failure 
by slowing renal failure progression. Studies on 
rennin-angiotensin-aldosterone have shown that 
ATII is formed in several ways other than through 
ACE, suggesting that ACEIs fail to inhibit the 
rennin-angiotensin-aldosterone system [1,3]. 
Furthermore, ACE is not a very specific enzyme 
and it has several substances other than ATI 
including bradykinin, substance P and 
neurokinins. ACEIs increase the levels of such 
substances [3-5]. Thus, ATII antagonists seem to 
provide a more specific effect than ACE inhibitors 
by blocking the effects of ATII at the receptor 
level.  
 
The main rationale for using an ACE inhibitor 
combined with an ATII receptor blocker is the 
ACE escape mechanism, wherein ATII and 
aldosterone levels return to pre-treatment levels 
despite continuous treatment with ACEIs. 
Combining two drugs reduces the effect of the 
ACE escape mechanism while maintaining the 
effect of ACE inhibitors on bradykinin cleavage 
[2,6]. In both clinical and experimental 
administrations, additional effects of dual 
blockage have been observed on both blood 
pressure and neuro-humoral activation. This 
shows that such combination therapy inhibits the 
effects of ATII more prominently than fixed dose 
treatment with ACEIs. This study demonstrates 
that combination therapy reduces proteinuria to a 
greater extent compared with treatment with 
enalapril or irbesartan alone. Corresponding 
decreases in serum albumin and proteinuria 
levels were observed in the patients. This may 
be due to a decrease in protein loss in urine. 
Dietary factors may have also contributed to this 
outcome. 
 
In the present study, it was observed that a 
decrease in proteinuria was independent of a 
decrease in MAP. The fact that a decrease in 
proteinuria becomes apparent in later periods of 
treatment, whereas a decrease in blood pressure 
become apparent at the end of the first month of 
treatment, suggests that a decrease in MAP is 
independent of a decrease in proteinuria [7-9]. 
Whereas a decrease in blood pressure can occur 
over the short-term (within hours), it takes about 
1 month for an anti-proteinuric effect to reach a 
maximal level. Hypertension leads to renal 
damage and this worsens hypertension. Now it is 
possible to break this vicious cycle by means of 
an early and efficient anti-hypertensive 
treatment. Such a treatment could be used in 
several nephropathies, especially in diabetic 
nephropathy. 
 
In a study of enalapril involving patients with non-
diabetic nephropathy, Apperloo et al [10] noted 
that arterial blood pressure was reduced 
significantly from 150 ± 22 / 91 ± 13 mmHg to 
132 ± 17 / 79 ± 10 mmHg. In a study on 
hypertensive patients with nephropathy, 
Gansevoort et al gave patients either 50 or 100 
mg losartan once daily. A decrease in mean 
blood pressure 24 h after the administration of 
the dose was found to be 9.2 % in the 50 mg 
losartan group and 10.9 % in the 100 mg 
losartan group. In that study, a significant 
difference was not found with respect to patients 
receiving 100 or 50 mg losartan [11].  
 
In this study, no significant difference was found 
between both groups in pre-treatment and post-
treatment serum creatinine levels. At the same 
time, no significant differences were found 
among any of the treatments with respect to 
serum creatinine levels. Reversible acute renal 
failure may occur on occasion in patients with 
diabetic nephropathy in whom proteinuria is at 
the nephrotic level. However, neither acute renal 
failure nor unexpected extreme increases in 
creatinine levels due to treatment were recorded 
in any patient during our follow-up observations. 
Doubling of the serum creatinine level in 583 
patients with nephropathy was found to be less 
common in the group receiving ACEI compared 
to the group receiving a placebo in the 
“Angiotensin-Converting-Enzyme Inhibition in 
Progressive Renal Insufficiency Study” [12] An 
important conclusion from that study is that 
ACEIs do not have a renoprotective effect in 
patients whose daily proteinuria is below 2 g. A 
renoprotective effect is observed when daily 
proteinuria is equal to or more than three g [13].  
 
In patients in whom diabetic nephropathy 
developed and GFR was reduced, it is likely that 
hyperkalaemia may develop due to blockage of 
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RAAS during treatment with both ACEIs and ATII 
receptor blockers. There is a higher risk of 
hyperkalaemia in patients with more prominent 
nephropathy and lower GFR [14,15]. Interstitial 
nephritis is commonly observed in such patients 
during course of diabetic nephropathy further 
increases the risk of hyperpotassemia by means 
of hyporenninemic hypoaldosteronism. Using 
ACEIs and ATII receptor blockers requires close 
laboratory and clinical monitoring of these 
patients. In the Irbesartan Diabetic Nephropathy 
Trial, it was observed that only 2 % of cases 
resulting from use of the drug had hyperkalemia 
enough to stop irbesartan [16].  
 
In a placebo-controlled study by Andersen et al 
[17] using 10/20 mg of enalapril and 50/100 mg 
of losartan in patients with type I diabetes 
mellitus, it was reported that serum potassium 
levels increased significantly compared to 
baseline levels in both treatments with 10 and 20 
mg of enalapril. Serum potassium levels did not 
change significantly in the groups given losartan. 
While serum potassium levels increased in the 
patients receiving enalapril, it was emphasized 
that the difference was not significant [17]. In a 
study by Gansevoort et al involving a group of 
hypertensive patients, it was reported that serum 
potassium levels increased more prominently as 
a result of administration of 100 mg of losartan 
compared to 50 mg of Losartan. This difference 
was reported to be clinically significant [11]. In 
The Losartan Heart Failure Survival Study-ELITE 
trial completed in 1997, the difference between 
pre-treatment and post-treatment serum 
potassium levels was significant in patients 
taking captopril, and no significant difference was 
found in the group receiving losartan [18].  
 
In the present study, no significant differences 
were found among the three groups in terms of 
pre-treatment and post-treatment serum 
potassium levels. At the same time, dangerous 
hyperkalemia requiring discontinuation of 
treatment did not develop in any patient. 
Reasons for no development of hyperkalemia 
may include restricting food enriched in 
potassium in the diet and relatively not high 
doses of the drugs given. In the cases reported 
in the literature, serious hyperkalemia developed 
when rather higher doses of drugs were given 
such as 20 mg of enalapril or 100 mg of 
Losartan. Again, if these patients are receiving 
potassium-sparing diuretics, the resulting 
increases in potassium levels may be dangerous 
[11]. 
 
The significant difference found between pre-
treatment and post-treatment HbA1c levels in 
this study may have been the result of several 
factors, including the close monitoring of 





Administration of enalapril, irbesartan and a 
combination of these two drugs to patients with 
diabetic nephropathy presenting with apparent 
proteinuria and azotemia results in apparent anti-
proteinuric effects. This effect is independent of 
the anti-hypertensive effects of the drugs. No 
serious side effects due to treatment were 
observed. They are therefore an efficient option 
for the treatment of proteinuria and hypertension 
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